In a phase 2 clinical study aimed to assess the efficacy of ganaxolone in Protocadherin 19 (PCDH19) clustering epilepsy enrolled 21 females aged 1-17 years with molecularly confirmed PCDH19 variants, experiencing at least 12 seizures during the 12-week screening period. Here, PCDH19 is linked to epilepsy.